Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (160)	9/23/2009 12:41:47 PM
From: John McCarthy	Read Replies (1) \| Respond to of 421

Hi Arthur Good price. I thought all this would happen - AFTER - the CC (-g-) Changing subject - OK? 1- They released PR today - new trial (macular edema secondary to retinal vein occlusion) pharout912 - posted this - What does a trial in CRVO mean.. I surmise 2-3 things 1) They are starting a trial and then can sell off label once approved. This is like the wet ARMD trial they have begun. This will allow them to expand the market on approval rapidly and also long term allow them to file for an expanded label. 2) Alimera which is back by some of the top healthcare venture funds (can you say Rockerfeller) is sponsoring the trial so they must have a strong feeling this will be successful..... I still think we see some PK results very soon... and a cash burn that is slowing faster than most think. ==================================== Is he suggesting that if IIuvien is FDA approved for DME then (off-label-wise) they will get the macular edema secondary to retinal vein occlusion market too? Just curious regards John